Shawn Iadonato (Ph.D. in Genetics, 1998; thesis advisor: Dr. Maynard Olson)
 Dr. Shawn Iadonato co-founded Kineta in December of 2007. As Chief Scientific Officer his principal responsibility is determining Kineta's research and development priorities. Dr. Iadonato also heads up both the scientific advisory and evaluation teams responsible for identifying and evaluating in-licensing and other developmental opportunities. Previously, Dr. Iadonato co-founded and served as CSO of Illumigen Biosciences, Inc. There, he pioneered Illumigen's patented drug discovery methodology which relied upon recruitment and screening of healthy populations. He also led the successful discovery and preclinical development of Illumigen's anti-Hepatitis C drug which ultimately resulted in the successful sale of the company in December, 2007. Prior to founding Illumigen, Dr. Iadonato managed the Human Genome Project data collection effort at the University of Washington Genome Center. He has also been central in several other large scientific collaborations and has served on a number of National Institutes of Health scientific review panels. He is co-inventor on more than 35 patents or pending applications, has been principal investigator on US federally funded research programs, and is frequently an invited lecturer. |
